A Natural Product Telomerase Activator As Part of a Health Maintenance Program

Calvin B. Harley,1,6 Weimin Liu,2 Maria Blasco,3 Elsa Vera,3 William H. Andrews,4 Laura A. Briggs,4 and Joseph M. Raffaele5

Abstract

Most human cells lack sufficient telomerase to maintain telomeres, hence these genetic elements shorten with time and stress, contributing to aging and disease. In January, 2007, a commercial health maintenance program, PattonProtocol-1, was launched that included a natural product-derived telomerase activator (TA-65®, 10–50 mg daily), a comprehensive dietary supplement pack, and physician counseling/laboratory tests at baseline and every 3–6 months thereafter. We report here analysis of the first year of data focusing on the immune system. Low nanomolar levels of TA-65® moderately activated telomerase in human keratinocytes, fibroblasts, and immune cells in culture; similar plasma levels of TA-65® were achieved in pilot human pharmacokinetic studies with single 10- to 50-mg doses. The most striking in vivo effects were declines in the percent senescent cytotoxic (CD8+/CD28−) T cells (1.5, 4.4, 8.6, and 7.5% at 3, 6, 9, and 12 months, respectively; p = not significant [N.S.], 0.018, 0.0024, 0.0062) and natural killer cells at 6 and 12 months (p = 0.028 and 0.00013, respectively). Most of these decreases were seen in cytomegalovirus (CMV) seropositive subjects. In a subset of subjects, the distribution of telomere lengths in leukocytes at baseline and 12 months was measured. Although mean telomere length did not increase, there was a significant reduction in the percent short (<4 kbp) telomeres (p = 0.037). No adverse events were attributed to PattonProtocol-1. We conclude that the protocol lengthens critically short telomeres and remodels the relative proportions of circulating leukocytes of CMV+ subjects toward the more “youthful” profile of CMV− subjects. Controlled randomized trials are planned to assess TA-65®-specific effects in humans.

Introduction

People take dietary supplements with the intent to preserve mental, physical, and emotional health and vigor into old age. Although drugs and surgical procedures that target diseases of the elderly will hopefully arrest or partially reverse tissue damage caused by aging and chronic stress, measures to maintain health are arguably a better approach to lengthening our healthy life span. Most dietary supplement programs include combinations of vitamins, antioxidants, and other constituents, some of which have been shown to have significant health benefits in controlled clinical studies, whereas others may show adverse effects,1–6 underscoring the need to assess functional effects of combination products. This paper presents initial data from an ongoing observational study of a novel dietary supplement program, PattonProtocol-1, which includes a natural product-derived telomerase activator targeting a fundamental aspect of cellular aging.

Telomerase is an enzyme that synthesizes the specific DNA sequence at telomeres, i.e., the terminal DNA at the ends of all chromosomes.7,8 Telomeres are essential genetic elements responsible for protecting chromosome ends from being recognized as “broken DNA.” Because telomeric DNA cannot be fully replicated by conventional DNA polymerases, and because telomeres undergo degradative processing and are a “hotspot” for oxidative damage,9 telomeres will gradually shorten with time and cell division unless there is sufficient telomerase activity to maintain telomere length.

1Geron Corporation, Menlo Park, California.
2TA Sciences, New York, New York.
3Spanish National Cancer Center, Madrid, Spain.
4Sierra Sciences, Reno, Nevada.
5PhysioAge Systems, New York, New York.
6Present address: Telome Health Inc., Menlo Park, California.
Telomerase is activated in fetal development, thus protecting telomeres from significant loss during this period of dramatic cell expansion. However, telomerase is repressed before birth in most somatic tissue, and, as a consequence, birth marks the beginning of telomere erosion in most tissues throughout life. Tissues with continual cell turnover or periods of rapid proliferation are “telomerase competent” in that they upregulate telomerase during early phases of progenitor expansion. All adult somatic stem cells appear to be capable of activating telomerase during tissue regeneration. However, these periods of activation are insufficient to prevent telomere loss, and this is compounded by a decreased ability to activate telomerase during aging and stress. In addition, stress can accelerate telomere loss by increasing cell turnover and the amount of telomeric DNA lost per cell division.

In cross-sectional studies, humans lose telomeric DNA at a very modest rate of about 15–60 bp per year, likely reflecting the small numbers of stem cells that are actively dividing in proliferative tissues compared to the total stem cell reserve, and the quiescent state of cells in other tissues. Telomere shortening has been investigated in human cells in culture, in human genetic diseases with mutated telomerase, and in animal models of telomerase deficiency. These studies point to a causal relationship between telomere loss, cell aging, reduced tissue regeneration, and loss of tissue structure and function. In support of this causal relationship, epidemiological studies show that short telomeres in humans are a risk factor for atherosclerosis, hypertension, cardiovascular disease, Alzheimer disease, infections, diabetes, fibrosis, metabolic syndrome, cancer, and overall mortality.

Chronic viral infections such as cytomegalovirus (CMV) and human immunodeficiency virus (HIV) accelerate telomere loss and premature aging of the immune system, especially the virus-specific cytotoxic T cells, responsible for killing infected cells. In addition to telomere loss, these cells often lack expression of the co-stimulatory receptor CD28 and have reduced proliferative capacity, reduced ability to secrete antiviral cytokines and chemokines, increased resistance to apoptosis, and compromised ability to lyse infected cells. About 50% of the U.S. population is infected with CMV as judged by circulating CMV-specific antibodies, but after an initial 30% seropositivity rate by age ≈10, there is ≈1% annual seroconversion rate throughout life leading to ≈90% seropositivity by the ninth decade. This linear increase has made it difficult to distinguish the effects of pure immunosenescence from those that can be attributed to this extremely common virus.

Here we report initial findings from a dietary supplement program which includes TA-65®, a purified small-molecule telomerase activator derived from an extract of a plant commonly used in traditional Chinese medicine. Telomerase activation and functional studies on a related molecule (TAT2) from the same plant have been previously reported for human skin keratinocytes and immune cells in culture. Effects of TAT2 in tissue culture studies with CD8+ T cells from HIV/acquired immunodeficiency syndrome (AIDS) subjects included increased replicative capacity, improved cytokine and chemokine responses to antigens, and increased killing of autologous HIV-infected CD4+ cells.

### Methods

**PattonProtocol-1**

PattonProtocol-1 was launched in January, 2007, by TA Sciences (New York) as a commercial age-management product composed of a natural product–derived telomerase activator (TA-65®, described below), a dietary supplement pack (online material S1), laboratory testing (Table 1), and physician counseling. All subjects signed a comprehensive Customer Acknowledgement Form. Baseline assays (Tables 1 and 2) indicated that most individuals were within the normal ranges for the majority of tests. In a small number of cases described in the Results section, the consulting physician prescribed medications for subjects based upon clinical tests. There was no qualitative change in the overall conclusions whether these subjects were included or censored from the analysis. We report results for all evaluable subjects who completed 12 months of the protocol by June, 2009. The number of subjects at 3, 6, 9, and 12 months for most tests was 43, 59, 27, and 37, respectively. The age and gender frequencies of the subset at each time point were similar to those of the total baseline population (n = 114; 63 ± 12 years, 72% male).

**TA-65®**

TA-65®, exclusively licensed to TA Sciences from Geron Corporation, is a >95% pure single chemical entity isolated from a proprietary extract of the dried root of Astragalus membranaceus and formulated into 5- to 10-mg capsules with inert excipients. Starting doses of 5–10 mg/day were considered safe on the basis of historical usage of extracts. Some subjects increased their dosage after several months on the product to 25–50 mg/day. Cumulative dose consumed during the year was recorded for each subject and used for preliminary dose–response analysis.

**Clinical laboratory assays**

At baseline and each time, point blood samples were drawn and shipped the same day at ambient temperature to analytical laboratories. Assays for standard blood counts, blood chemistry, specialized immune subsets, CMV antibody titer, and inflammation markers were conducted at Quest Diagnostics or Bio-Reference Laboratory. Specialized immune subset analyses were conducted at UCLA Clinical Laboratories and Pathology Services.

**Telomerase activity assay in cultured human keratinocytes and fibroblasts**

Telomerase activity was measured in human neonatal keratinocytes (Cascade Biologies, Portland, OR) and MRC5 fetal human fibroblasts (ATCC# CCL-171) pre-and posttreatment in culture with TA-65® using the telomere repeat amplification protocol (TRAP) assay, essentially as described elsewhere. In brief, telomerase activity was measured in actively growing cells incubated for 24–48 h with TA-65® in the vehicle (dimethylsulfoxide [DMSO]) at 1% vol/vol [keratinocyte culture] or 0.5% [fibroblasts]) versus vehicle alone. Measurements were typically made at 5–10 population doublings (PD) (keratinocytes) or 30–40PD (fibroblasts). Telomerase reaction products were resolved by
### Table 1. Assays and Biomarkers

<table>
<thead>
<tr>
<th>Potential safety and informational assays</th>
<th>Exploratory biomarker assays</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Blood count</strong></td>
<td><strong>Blood sugar and insulin</strong></td>
</tr>
<tr>
<td>Basophils (%), eosinophils (%), hematocrit, hemoglobin, lymphocytes (%), MCH, MCHC, MCV, monocytes (%), MPV, neutrophils (%), platelet count, RBC, RDW, WBC</td>
<td>Glucose, hemoglobin A1C, serum insulin</td>
</tr>
<tr>
<td><strong>Viral antibody</strong></td>
<td><strong>Inflammation biomarker</strong></td>
</tr>
<tr>
<td>CMV IgG</td>
<td>Cardio CRP, homocysteine</td>
</tr>
<tr>
<td><strong>Kidney function</strong></td>
<td><strong>Immune biomarkers</strong></td>
</tr>
<tr>
<td>BUN/creatinine ratio, calcium, chloride, CO₂, creatinine, phosphorus, potassium, sodium, urea nitrogen, uric acid</td>
<td>CD8⁺/CD28⁻ gated on CD3 (%), CD8⁺/CD28⁻ gated on CD8 (%), CD8⁺/CD95⁺ gated on CD3 (%), CD8⁺/CD95⁺ gated on CD8 (%)</td>
</tr>
<tr>
<td><strong>Liver function</strong></td>
<td><strong>Cardiovascular Biomarkers</strong></td>
</tr>
<tr>
<td>A/G ratio, albumin, alkaline phosphatases, ALT, AST, bilirubin direct, bilirubin total, GGT, calculated globulin, LDH (LD), total protein</td>
<td>Sphygmocor assays, systolic blood pressure, diastolic blood pressure</td>
</tr>
<tr>
<td><strong>Endocrine function (also as exploratory biomarkers)</strong></td>
<td><strong>Pulmonary biomarkers</strong></td>
</tr>
<tr>
<td>DHEA sulfate, estradiol, FSH, IGF-BP3, IGF-1, LH, progesterone, PSA total, SHBG, T3 (free &amp; total), T4 total, testosterone (free, %free, and total), TSH third generation</td>
<td>Spirometry FEV1, spirometry FVC</td>
</tr>
<tr>
<td><strong>Cholesterol (also as exploratory biomarkers)</strong></td>
<td><strong>Skin biomarkers</strong></td>
</tr>
<tr>
<td>Cholesterol/HDL ratio, cholesterol total, HDL cholesterol, calculated LDL cholesterol, triglycerides</td>
<td>Forearm cutometer measurements</td>
</tr>
<tr>
<td><strong>Iron</strong></td>
<td><strong>Vision biomarkers</strong></td>
</tr>
<tr>
<td>Ferritin, iron (total and saturated), TIBC</td>
<td>Contrast sensitivity (left/right eye)</td>
</tr>
<tr>
<td><strong>Vitamins (also as exploratory biomarkers)</strong></td>
<td><strong>Cognitive biomarkers</strong></td>
</tr>
<tr>
<td>Serum folate, serum vitamin B12, vitamin D (25-OHD₂, 25-OHD₃, 25-OH total)</td>
<td>Central nervous system vital signs panel</td>
</tr>
<tr>
<td><strong>Other</strong></td>
<td><strong>Telomere biomarkers</strong></td>
</tr>
</tbody>
</table>
| Height, weight                           | Height, weight |}

**Table Notes:**
- Abs; MCH, mean corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin concentration; MCV, mean corpuscular volume; MPV, mean platelet volume; RBC, red blood cells; RDW, Red cell distribution width; CMV IgG, cytomegalovirus immunoglobulin G; CRP, C-reactive protein; BUN, blood urea nitrogen; A/G ratio, albumin/globulin ratio; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma glutamyl transpeptidase; LDH, lactate dehydrogenase; LD, DHEA, dehydroepiandrosterone; FSH, follicle-stimulating hormone; IGF-BP3, insulin-like growth factor binding protein 3; IGF-1, insulin-like growth factor-1; LH, lutenizing hormone; PSA, prostate-specific antigen; SHBG, sex hormone-binding globulin; T₃, triiodothyronine; T₄, thyroxine; TSH, thyroid-stimulating hormone; FEV₁, forced expiratory volume during 1st second; FVC, forced vital capacity; HDL, high-density lipoprotein; LDL, low-density lipoprotein; TIBC, total iron-binding capacity; 25-OHD₂, 25-dihydroxyvitamin D₂; 25-OHD₃, 25-dihydroxyvitamin D₃; 25-OH total, total 25-hydroxyvitamin D; FlowFISH, Flow-fluorescent in situ hybridization; WBC, white blood cells; qPCR, quantitative polymerase chain reaction.
| Table 2. Baseline Values for Selected Biomarkers, Relevant Blood/Immune Variables, and Relationship to Age |
|-------------------------------------------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|
| Age (Mean ± SD)                                 | Lymphocyte telomere length (Mean ± SD) | Granulocyte telomere length (Mean ± SD) | CMV IgG Antibody titer (UCLA) | WBC (UCLA) | # Lymphocytes (UCLA) | % CD3 (UCLA) | % CD8 (UCLA) | % CD8+CD28+ T cells (UCLA) | # CD8 (UCLA) | % CD8+CD28+ T cells (UCLA) | # CD8+CD28+ T cells (UCLA) | % CD8+CD28+ T cells (UCLA) | R squared | p value |
| Mean 62.5 ± 12.5                               | 5.73 ± 1.25 kb | 6.71 ± 0.88 kb | 1.83 ± 0.07 | 5690 ± 1850 | 70.1 ± 1320 | 22.8 ± 435 | 34.7 ± 175 | 0.011 ± 0.002 | 0.012 ± 0.003 | 0.055 ± 0.001 | 0.190 ± 0.030 | 0.023 ± 0.004 | 0.11 ± 0.025 | 0.25 ± 0.070 |
| SD 12.5 ± 2.5                                   | 1.05 ± 0.15 kb | 0.88 ± 0.17 kb | 1.77 ± 0.12 | 1520 ± 565 | 8.57 ± 479 | 9.14 ± 250 | 19.9 ± 180 | 0.011 ± 0.002 | 0.012 ± 0.003 | 0.055 ± 0.001 | 0.190 ± 0.030 | 0.023 ± 0.004 | 0.11 ± 0.025 | 0.25 ± 0.070 |
| n 114 ± 11 ± 114                               | 114 ± 114      | 114 ± 114      | 114 ± 114 | 114 ± 114 | 114 ± 114 | 114 ± 114 | 114 ± 114 | 114 ± 114 | 114 ± 114 | 114 ± 114 | 114 ± 114 | 114 ± 114 | 114 ± 114 | 114 ± 114 |
| m 55 ± 55 bp                                     | 34 ± 34 bp      | 34 ± 34 bp      | 34 ± 34 bp | 34 ± 34 bp | 34 ± 34 bp | 34 ± 34 bp | 34 ± 34 bp | 34 ± 34 bp | 34 ± 34 bp | 34 ± 34 bp | 34 ± 34 bp | 34 ± 34 bp | 34 ± 34 bp | 34 ± 34 bp |
| R squared 0.42 ± 0.04                         | 0.24 ± 0.08     | 0.06 ± 0.01     | 0.01 ± 0.01 | 0.01 ± 0.01 | 0.01 ± 0.01 | 0.01 ± 0.01 | 0.01 ± 0.01 | 0.01 ± 0.01 | 0.01 ± 0.01 | 0.01 ± 0.01 | 0.01 ± 0.01 | 0.01 ± 0.01 | 0.01 ± 0.01 | 0.01 ± 0.01 |
| p value 4.8E-15                               | 4.3E-13         | 3.1E-8          | 2.7E-9     | 1.3E-6      | 2.4 ± 1.1E-6 | 2.3 ± 1.1E-6 | 2.2 ± 1.1E-6 | 2.1 ± 1.1E-6 | 2.0 ± 1.1E-6 | 2.0 ± 1.1E-6 | 2.0 ± 1.1E-6 | 2.0 ± 1.1E-6 | 2.0 ± 1.1E-6 | 2.0 ± 1.1E-6 | 2.0 ± 1.1E-6 |

### Notes

- Lymphocyte and granulocyte telomere lengths are from FlowFISH analyses.
- For some subjects, CMV antibody titers were first taken at a postbaseline time point.
- Replicate blood samples were collected and sent to UCLA Clinical Labs for analyses which focused on assessment of senescent CD8+CD28+ T cells, and to Quest Diagnostics for routine blood counts. Differences in numbers for the same lab analysis likely reflect variations between laboratory techniques. Table entries represent data from Quest except where UCLA is indicated.
- Slope of the linear regression line of variable indicated versus age of donor.
- Number and percent CD8+CD28+ cells were derived from the measured number of CD8+CD28+ and total CD8+ cells.
- CMV, Cytomegalovirus; IgG, immunoglobulin G; SD, standard deviation; NK, natural killer; WBC, white blood cells; DHEA, 5-dehydroepiandrosterone; LDL, low-density lipoprotein; SBP, systolic blood pressure; DBP, diastolic blood pressure; FlowFISH, Flow fluorescence in situ hybridization.
electrophoresis on nondenaturing polyacrylamide gels and quantified by exposure to Phosphor Screens and imaging on Phospholmage SL (Molecular Dynamics).

**Telomere length assays**

Median telomere length in peripheral lymphocytes and granulocytes was determined by FlowFISH at Repeat Diagnostics (Vancouver, Canada) essentially as described elsewhere. Mean telomere length by qPCR was performed in the laboratory of Dr. Richard Cawthon (University of Utah, Salt Lake City, UT). High-throughput quantitative fluorescence in situ hybridization (HT qFISH) was performed at CNIO, Madrid, for inter- and intranuclear telomere length distributions.

**Statistics**

Data from this study were collected primarily as a hypothesis-generating exercise because subjects were not participating in a controlled prospective study, and statistical analyses were not formally defined a priori. Baseline data were analyzed for cross-sectional age effects. Student t-tests were used for comparison of means and the F-distribution for significance of linear regression against subject age. Except where indicated, two-tailed paired t-tests were conducted at each time point for comparisons to the baseline values. For percentage of short telomeres analyzed by HT qFISH, individual differences between baseline and post-product data were analyzed by chi-squared analysis.

**Results**

**Mechanism of action**

TA-65 activates telomerase in human neonatal keratinocytes and fetal fibroblasts in culture. TA-65 upregulates telomerase activity in low- and mid-passage human neonatal keratinocytes two- to three-fold in a dose-responsive manner (Fig. 1A). In these studies, activation was two- to three-fold at the lowest concentrations tested (30–100 nM), and activation was not as great at higher concentrations. This pattern is similar to that seen for TAT2, a related molecule tested in human immune cells. The ability of TA-65 to upregulate telomerase activity was also tested in human fetal fibroblasts (MRC5) over a broad concentration range (Fig. 1B). Untreated and vehicle (DMSO)-treated MRC5 cultures showed extremely weak telomerase activity; there was essentially no telomerase extension products with a size greater than that of T1, the minimum size needed to detect a product in the TRAP assay. Results from three independent experiments indicated that TA-65 at concentrations as low as 1 nM induced processive telomerase activity in MRC5 cells. Telomerase activation by TA-65 in the 1–30 nM range in multiple cell types is important, because plasma levels of TA-65 are typically in the 1–20 nM range 4–8 h postoral ingestion of 5–100 mg TA-65 (unpublished data).

**Baseline observations**

The relationships between age and various biomarkers including telomere length have been reported in a number of cross-sectional studies. Table 2 shows mean values, standard deviations, count, slope, and R² from linear regression on subject age, and the statistical significance of the slope for the baseline tests investigated in this report. As expected, this population showed a highly significant decline as a function of client age in both lymphocyte and granulocyte telomere length by FlowFISH analysis, and the slopes of the decline (55 and 34 bp/year; p = 10⁻¹⁵ and 10⁻⁸, respectively) are comparable to those reported previously. Age-dependent increases are seen in the percent senescent (CD8⁺CD28⁻) cytotoxic T cells, percent natural killer (NK) cells, and percent and absolute number of neutrophils. Significant
FIG. 2. Baseline telomere length and immune subset data as a function of subject age segregated by cytomegalovirus (CMV) status. Overall baseline data without segregation by CMV status is provided in Table 2. Correlations with age for lymphocyte and granulocyte telomere length (A,B) and immune subsets (C–J) at baseline were determined by linear regression in the CMV+ and CMV− subjects. Telomere length and immune parameters were analyzed by flow cytometry as described in Methods.
age-dependent decreases are seen in naïve (CD8\textsuperscript{+},CD95\textsuperscript{−}) cytotoxic T cells, B cells, and lymphocytes. Because CMV infection can have a significant impact on immune markers,\textsuperscript{37,46} we analyzed the age dependency of baseline immune subsets by CMV status (Table 2 and Table 3). Lymphocyte, but not granulocyte, telomere length was longer in CMV\textsuperscript{−} subjects than that in CMV\textsuperscript{+} subjects, suggesting that CMV infection drives increased turnover (and hence telomere shortening) in lymphocytes but has relative little effect on hematopoietic stem cells. Telomere length in granulocytes is considered a surrogate of telomere length in hematopoietic stem cells due to their short transit time to peripheral blood, and short half-life in circulation.\textsuperscript{42} The ages of the CMV\textsuperscript{+} and CMV\textsuperscript{−} subjects (65 ± 12 and 62 ± 13, respectively) were not significantly different, but the mean lymphocyte telomere length in CMV\textsuperscript{−} individuals was 680bp less than that observed in the CMV\textsuperscript{+} group (p = 0.003), suggesting an acceleration of aging by about 10 years in the CMV\textsuperscript{+} group based on −53bp per year for lymphocytes.

As expected, baseline numbers and the rate of increase in senescent cytotoxic T cells (CD8\textsuperscript{+}/CD28\textsuperscript{−}) in percent and absolute counts was highest in the CMV\textsuperscript{+} population (Table 3 and Fig. 2C,D). The slight increase in per cent of senescent cytotoxic T cells as a function of age in CMV\textsuperscript{+} subjects (Fig. 2C) despite declining absolute numbers of these cells (Fig. 2D) is a consequence of a significant decline in total CD8\textsuperscript{+} cells as a function of donor age in CMV\textsuperscript{−} subjects (Fig. 2E,F). The difference in the mean number of CD8\textsuperscript{+} T cells between CMV\textsuperscript{+} and CMV\textsuperscript{−} subjects (208 cells/μL) is essentially accounted for by the difference in mean number of senescent CD8\textsuperscript{+} T cells between these two subpopulations (200 cells/μL) (Table 3). Although the %CD8\textsuperscript{+}/CD28\textsuperscript{−} cells at baseline was significantly higher in CMV\textsuperscript{−} subjects (p < 0.0001), this was due primarily to the elevated absolute number of CD8\textsuperscript{+}/CD28\textsuperscript{−} cells in the CMV\textsuperscript{+} subset (i.e., an increased denominator for the CMV\textsuperscript{+} group). The absolute number of nonsenescent cytotoxic T cells (CD8\textsuperscript{+}/CD28\textsuperscript{−}) was not significantly different between CMV\textsuperscript{+} and CMV\textsuperscript{−} subjects (Table 3).

CMV\textsuperscript{+} subjects had significantly fewer absolute and percent naïve cytotoxic T cells (CD8\textsuperscript{+}/CD95\textsuperscript{−}) at baseline than did CMV\textsuperscript{−} subjects (p < 0.0005 and 0.07, respectively) (Table 3), but in both populations there was dramatic reduction in the absolute and relative abundance of these cells as a function of subject age (Fig. 2 G,H), consistent with previous studies.\textsuperscript{47,48} In 80- to 90-year-old subjects, there were <50 naïve CD8\textsuperscript{+} cells/μL.

A novel finding in the baseline dataset is an apparent effect of CMV infection on neutrophils: CMV\textsuperscript{−} subjects show an increase in neutrophil number and percentage as a function of subject age compared to an essentially flat profile with age for the CMV\textsuperscript{+} subjects (Fig. 2I,J). At baseline, the mean number of neutrophils in CMV\textsuperscript{−} subjects was about 20% higher than that in CMV\textsuperscript{+} subjects (p = 0.02 by absolute counts, p = 0.003 by %) (Table 3). There was also highly significant increase in baseline percent (p = 0.00015) and absolute numbers of NK cells (p = 0.006) in the total population (Table 2), but there was no significant difference between CMV\textsuperscript{+} and CMV\textsuperscript{−} subjects.

### Changes from baseline

Reduction in percent cells with short telomeres. Two independent measures of median or mean telomere length (by FlowFISH and qPCR) showed no consistent change with time on PattonProtocol-1 (data not shown). However, we also analyzed the distribution of individual telomere lengths using automated high-throughput confocal microscopy (HT qFISH\textsuperscript{42}). Telomere signals within the nuclei of white blood cells were analyzed from 13 subjects at baseline and a follow-up time point between 12 or 18 months. Mean telomere length by HT qFISH correlates relatively well with median telomere length by FlowFISH (supplemental data S2) and although some individuals showed a significant increase or decrease (Fig. 3A), overall there was no significant decline in mean telomere length by HT qFISH (p = 0.29). However, HT qFISH revealed a decline in the percentage of nuclei with short telomeres (<4kbp) in 10 of the 13 individuals (p < 0.05 for 7 of those 10) at 12–18 months compared to baseline, while only one of the remaining 3 individuals had a significant increase in percent short telomeres (Fig. 3B). Given these data, we used a one-tailed paired t-test to determine the probability that the overall mean reduction across all 13 subjects was due to chance (p = 0.038). In separate studies in murine cells in culture and in vivo we have shown that TA-65 alone will reduce the percentage of cells with short telomeres with minimal effects on mean telomere length (M.B., manuscript in preparation).

Positive remodeling of the immune system. There were a number of striking changes from baseline in the adaptive and innate immune system of subjects on PattonProtocol-1. We saw statistically significant “age-reversal” effects in the
number and percent of senescent (CD8⁺CD28⁻) cytotoxic T cells, particularly after 3 months (Fig. 4A). Senescent CD8⁺CD28⁻ T cells dropped with a linear trend from roughly 39% in the baseline population to about 36% at 12 months in the overall population (p = 0.0068 at 12M). Most of this effect was due to a 20% drop in the number of CD8⁺CD28⁻ cells in the CMV⁺ population (Fig. 4D, p = 0.0044 at 12M). This decrease, relative to the age-related increase of 0.57%/year and 3 CD28⁻ cells/year in CMV⁺ individuals, represent an apparent age reversal of &5–20 years in this biomarker of immune aging.

At baseline, CMV⁺ individuals had a significantly lower number and percent of neutrophils compared to CMV⁻ individuals (Table 3). After 3 months on PattonProtocol-1, there was an overall increase in number and percent of neutrophils (Fig. 4B) which was primarily driven by the effects of the Protocol in the CMV⁺ subjects (Fig. 4D), suggesting that as in the case with CD28⁻ cells, PattonProtocol-1 may reverse a potentially detrimental effect of CMV infection on neutrophils.

The percent and number of NK cells significantly decreased after about 6 months on product (Fig. 4C). A decrease was observed in both CMV⁺ and CMV⁻ individuals, but again the effect was more pronounced in the CMV⁺ population (data not shown). The changes at 12 months in the overall population (about a 15% decline in both % and
number of NK cells) was highly significant ($p = 0.0035$ and $0.0021$ for number and percent cells, respectively), and dramatic compared to the baseline increases per year in NK cells for the CMV$^+$ group ($+2.4$ cells per year and $+0.3\%$ per year).

**Discussion and Conclusions**

The inability to maintain telomeres with age and chronic stress has been linked to declining health and the increased risk of disease and death from many causes, including cancer.\(^{16,25,49-52}\) In this study, we report that a 1-year health maintenance program consisting of a dietary supplement pack combined with a natural product–derived telomerase activator results in a decreased percentage of short leukocyte telomeres and remodeling of the relative proportions of the circulating leukocytes of CMV$^+$ subjects toward the more “youthful” profile of CMV$^-$ subjects.

One of the strengths of our study is the low CMV-positivity rate (54%) in a relatively older population, which allows us to separate the effects of age and CMV status on immunosenescence. It also serves to mitigate one of our study’s weaknesses—the lack of a control group—as the subjects were initially unaware of their CMV status and their subsequent knowledge is unlikely to have caused the segregation of many of the effects of the protocol by CMV status.

Our description of the decrease in CD8$^+$CD28$^-$ T cells as a positive remodeling of the immune system is supported by the increased morbidity and mortality associated with what is known as the immune risk profile (IRP). This profile has been defined as a CD4/CD8 less than 1 in association with CMV seropositivity by longitudinal studies of individuals in their eighties and nineties in the OCTO/NONA Swedish cohort.\(^{53}\) As in our cohort, the major driving force for the decreased CD4/CD8 in CMV$^-$ subjects in this population is likely the accumulation of virus-specific CD8$^+$CD28$^-$ T cells. These studies have reported 6-year follow-up data, and no individuals who have survived to 100 years old exhibit the IRP, even if they are CMV$^+$. The authors conclude that successful immune aging entails being able to control CMV infection without accumulating senescent cytotoxic T cells. Thus, we conclude that the 20% reduction in CD8$^+$CD28$^-$ T cells is a salutary effect, even though we have yet to see increases in the number of CD8$^+$CD28$^+$ T cells. Telomere shortening associated with replicative senescence is the probable cause of loss of CD28 expression and apoptosis resistance of CD8$^+$ T cells.\(^{54}\) The decrease in the percentage

**FIG. 4.** Relative changes from baseline as a function of time (months) for immune subsets. The mean of the absolute change from baseline for each parameter across all subjects for which data at that time point was calculated and then expressed as a percent change from the mean value at baseline for those subjects. In A–C, data for both cytomegalovirus-positive (CMV$^+$) and CMV$^-$ subjects are combined. (D) Relative mean change is shown for the CMV$^+$ population subpopulation only. Asterisks next to a data point signifies $p < 0.01$ (**), $p < 0.05$ (**), and $p < 0.1$ (*) for a two-tailed paired (within-subject) t-test analysis comparing baseline to time point values.
of short telomeres we found makes upregulation of telomerase by TA-65 the most likely mechanism for this salutary effect.

Age-related changes in the innate immune system have not been as well characterized as those of the adaptive immune system, although the importance of changes in the former is increasingly being recognized. It is generally agreed that the per-cell activity of neutrophils as measured by oxidative burst, phagocytosis, and chemotaxis decreases with age. There is less agreement on the effect of aging on neutrophil number which has been variously reported to be preserved, decreased, or increased with age. CMV status is not reported in the first two studies, but in the last study from the above-mentioned NONA cohort, the increase in neutrophil number is based on a comparison between 18 middle-aged (55-year-old) subjects with a 55% CMV+ prevalence rate and 120 very old subjects (92–100-year-old) with an 87% CMV+ prevalence rate. Most of the cross-sectional increase of 960 neutrophils occurs within the 92 to 100 year olds, with only a 52-cell increase between 55 and 92. There is also a significant longitudinal increase over a 6-year interval in the very old group. This suggests that there is selection for those older subjects able to increase their circulating neutrophils in the face of deteriorating tissues, increased inflammation, and increased exposure to infectious agents. Our novel finding that by age 62 the neutrophil number is 20% higher and continues to increase with age only in CMV+ subjects can be interpreted as a compensatory increase in the face of declining per cell activity and barrier function, as well as increased antigenic load. The absence of a cross-sectional increase with age in neutrophil number in CMV+ subjects suggests that this compensation is blocked in the CMV+ subjects perhaps due to inhibitory cytokine production by the senescent T cells. The effect of the protocol to increase neutrophil count in CMV+ subjects can be interpreted as a salutary removal of this block in part through reduction in the number of senescent T cells.

There is a broad consensus that NK cell number increases with age to compensate for decreased per-cell activity, which results from impaired signal transduction, but other mechanisms such as decreased barrier function and increased antigenic/pathogenic load may also contribute to increased NK cells with age. The decrease in NK cell number induced by the protocol is an “age reversal,” but because we did not measure NK activity we cannot say whether it is from improved barrier function or improved signal transduction. Unlike other cells of the innate immune system, NK cells proliferate after activation and experience further telomere shortening once they are released from the bone marrow. The decrease in the percentage of short telomeres we found could result in improved signal transduction as a mechanism for the reduction in NK cell number. Taken together, these three changes in leukocyte number induced by the protocol represent a remodeling of the immune systems of CMV+ subjects to look more like those of CMV- subjects and successfully aging CMV+ centenarians.

Physicians who monitored the health of the current study subjects through 1 year on the product reported no adverse events that were likely related to the protocol. However, 2 subjects who recently escalated their daily dose reported feeling “anxious” on 100 mg/day but not when they switched back to 50 mg/day. A placebo-controlled study will be needed to determine if this potential adverse effect is real. No new cases of cancer or cardiovascular disease were reported during the overall 260 person-years of dosing with Patton-Protocol-1 through June, 2010, and this is statistically significant (p < 0.05, cancer; p < 0.02, CVD ) assuming baseline age-specific risks in our population were similar to those of the U.S. population.

TA-65+ activated telomerase in cultured human cells at concentrations seen in the plasma of subjects on the protocol. Paradoxically, although ≈40% of subjects showed an increase in mean telomere length over time, on average across all subjects there was a nonsignificant decline in mean telomere length. However, we speculate this effect is explained by cell dynamics and the fact that telomerase preferentially lengthens the shortest telomeres. Rescue and selective expansion of near-senescent cells with short telomeres could lead to a reduction in the population mean telomere length despite some lengthening of telomeres in all cells. Because detrimental effects of telomere loss are primarily driven by short, dysfunctional telomeres, and loss of tissue function and disease onset in proliferative tissues have been associated with telomere lengths <4 kbp, we believe that our observed reduction in telomeres <4 kbp in subjects on Patton-Protocol-1 is a significant, positive response, and that TA-65+ contributes to the apparent benefit of the dietary supplement. In support of this, studies with TA-65+ given orally in old mice showed similar reductions in percent cells with short telomeres and positive functional effects on tissues (Blasco et al., submitted) and preliminary dose–response analyses showed an increase in salutary effects with TA-65+ doses up to 20–30 mg per day average compared to the initial 5- to 10-mg per day dose (data not shown). Finally, analysis of additional biomarkers of aging in subjects on PattonProtocol-1 suggest improvements in the cardiovascular system, metabolism, and bone mineral density, which will be further studied and reported elsewhere. Independent randomized controlled studies with TA-65+ alone are planned.

Acknowledgments

We thank Drs. Tom Okarma, Spencer Brown, and Rita Effros for critical review of the manuscript, and Noel Patton for patience, encouragement, and financial support of the studies. We also thank the early telomerase activation team at Geron Corporation for generating data in human keratinocytes, Marissa Chunisingh for acting as a key interface between clients and TA Sciences staff, and Drs. Nathan Wong and Sherman Xi for critical feedback and help with statistical analyses.

Author Disclosure Statement

Calvin Harley is one of the inventors of TA-65. He consults for TA Sciences and is personally taking TA-65 and is one of the subjects studied to generate data for this article. He owns stock and stock options in Geron Corporation, a company that is developing telomerase activators for therapeutic purposes and the company that licensed TA-65 to TA Sciences. He is co-founder, President, and CEO, and holds stock in Telome Health, Inc., a diagnostics company that will provide telomere- and telomerase-related assay services to the healthcare industry. Joseph Raffaele consults for TA Sciences; he is CEO of PhysioAge Systems, LLC, a company that provides bi-

54

HARLEY ET AL.
TELOMERASE ACTIVATOR TA-65 FOR HEALTH MAINTENANCE

55

markers of aging analysis, including telomere lengths, to medical practices, and he is co-founder of PhysioAge Medical Group which offers TA-65 through the Patton Protocol. William H. Andrews owns stock or membership options in Geron Corporation and Sierra Sciences; he consults for TA Science, is a client of TA Sciences who is taking TA-65, and is one of the subjects studied to generate data for this manuscript. He is the founder, President, and CEO of Sierra Sciences, a company that develops therapeutics for inducing telomerase expression and has provided financial support for some of the studies described in this manuscript. Weimin Liu is an employee of TA Sciences. Elsa Vera and Maria Blasco have no competing financial interests.

References


Address correspondence to:
Calvin B. Harley
Telome Health, Inc.
1455 Adams Drive
Menlo Park, CA 94025

E-mail: charley@telomehealth.com

Received: June 25, 2010
Accepted: August 9, 2010